A lean and focused diagnostic company
Immunovia AB (publ.) is a lean, focused diagnostic company seeking to revolutionize early detection of pancreatic cancer. We aim to improve outcomes for people at high risk of pancreatic cancer by detecting the disease at Stage 1 or 2 with our highly accurate blood test, PancreaSure. Immunovia plans to launch PancreaSure in the United States in the second half of 2025.
Immunovia was founded in Lund, Sweden based on protein research at Lund University. The company’s clinical lab and many of its employees are in the U.S.A., the company’s first commercial market.
Immunovia stock trades on the Nasdaq Stockholm exchange under the ticker symbol IMMNOV.
To learn more about investing in Immunovia click the button below.
Important Recent Events
Began development of the next-generation test
In Q3 2022, Immunovia initiated development of its next-generation test for early detection of pancreatic cancer. The Company sought to identify new, more accurate biomarkers to increase test performance. In November 2022, Immunovia entered into an agreement with the Swiss company Proteomedix AG to access their extensive experience in developing protein-based assays to detect cancer.
Jeff Borcherding promoted to CEO
To streamline operations and increase focus on the American market, Immunovia’s board of directors appointed Jeff Borcherding as CEO in April 2023. Jeff had previously led the Company’s US operations since joining Immunovia a year earlier. He immediately began a strategic review to identify changes needed to ensure the success of the Company.
Initiated a transformation of Immunovia
The company began a broad and sweeping transformation in July 2023. The transformation was intended to significantly lower costs, increase productivity, and drive speed. Immunovia discontinued the IMMray PanCan-d test to focus resources on its next-generation test. The Company also transitioned to the commercially available ELISA platform to enable faster and less expensive testing compared to the previous proprietary IMMray® platform. Finally, staffing and operating expenses were substantially reduced.
Successfully completed the discovery phase of the next-generation test
The discovery study marked a critical milestone in the development of Immunovia's next-generation test for early detection of pancreatic cancer. Over a dozen proteins were identified that can be used to detect stage I and II pancreatic ductal adenocarcinoma (PDAC) in the blood. This was the most comprehensive pancreatic cancer proteomics study to date and used the Olink platform to explore nearly 3,000 protein biomarkers. The promising biomarkers identified in the discovery study were then transitioned to the ELISA platform for further testing.
Positive results from the model development study
The next-generation test for pancreatic cancer achieved both the primary and secondary endpoints in a model development study. In the study, Immunovia's next-generation test demonstrated a specificity of 98% and a sensitivity of 75% for detecting early stages (1 and 2) of PDAC (pancreatic ductal adenocarcinoma), a highly aggressive and the most common form of pancreatic cancer. Immunovia's test was also significantly more accurate than CA19-9, the biomarker typically used for detecting pancreatic cancer.
Moved the laboratory to Research Triangle Park, North Carolina
To further streamline operations and reduce costs, Immunovia moved its lab and US headquarters to Research Triangle Park, North Carolina in May 2024. The new lab in RTP is smaller and more cost-effective than the prior lab in Marlborough, Massachusetts. The RTP market also offers a rich and cost-effective labor market, enabling Immunovia to staff the lab with talented employees at a lower cost.
Positive data from the VERIFI study
Immunovia announced positive results from the VERIFI study, the second clinical validation study of its next-generation pancreatic cancer test. The study met its primary endpoint, with the test successfully detecting 77% of stage I and II cases of pancreatic cancer. The completion of a second successful clinical validation study will strengthen Immunovia’s efforts to secure insurance reimbursement for its test.
PancreaSure – Immunovia’s brand name for next generation test
Immunovia announced PancreaSure as the brand name for its next-generation test for early detection of pancreatic cancer. PancreaSure is a simple blood test, with performance that meets or exceeds that of the most common screening methods used today. The name PancreaSure embodies the benefit of accurate pancreatic cancer detection.
Recognition for CLARITI study at prestigious scientific conferences
Immunovia’s CLARITI study selected to be a part of the distinguished plenary session at Digestive Disease Week (DDW) 2025 and was further recognized in the conference's closing session, Best of DDW. Also, CLARITI selected for poster presentation at scientific Workshop Poster Session of the Early Detection Research Network (EDRN), a cancer early-detection program established by the U.S. National Cancer Institute. These event reflect the growing recognition of Immunovia’s scientific progress and the momentum behind its diagnostic test, PancreaSure.
Leadership
Immunovia’s executive team has blended scientific, clinical and commercial expertise to build the leading company in early detection of pancreatic cancer. They learned best practices at many of the world’s top life science companies and learned to move quickly and operate efficiently at high-growth early stage companies.
Jeff Borcherding
Norma Palma, PhD
Lisa Ford, PhD, HCLD
Tom King, MD, PhD
Board of Directors
Immunovia has assembled a diverse and cohesive board with expertise in multiple areas to successfully guide the company through both test development and commercialization.
Peter Høngaard Andersen, MD
Valerie Bogdan-Powers
Melissa Farina
Bryan Riggsbee
Martin Møller
Hans Johannsson
Join our mission
At Immunovia, our talented, diligent team members are the driving force behind our success. We are a small, efficient, and collaborative group of individuals committed to achieving our mission detecting pancreatic cancer and saving lives. As we continue to grow and innovate, we’re excited to offer new roles to passionate individuals who want to make a real difference for people at high risk for pancreatic cancer. If you’re ready to be part of a forward-thinking team dedicated to transforming healthcare, we invite you to explore our open positions on LinkedIn. Take the next step in your career and help us in our mission to save lives. We can’t wait to connect with you!
Contact us
Email:
info@immunovia.com
Visiting address:
Medicon Village
Scheelevägen 2,
Lund
Postal address:
Immunovia AB
Medicon Village
SE-223 63 Lund
Email:
info@immunovia.com
Visiting address:
800 Capitola Dr. Suite 1
Durham, NC 27713
Postal address:
Immunovia
6409 Fayetteville Rd.
Suite 120-364
Durham, NC27713
Email:
helloir@immunovia.com
Jeff Borcherding
CEO
©2025 Immunovia. All rights reserved